EcoDrugPlus

Proteasome 20s Subunit Beta 10

Ensembl ID : ENSUAMG00000020721
Gene Symbol: PSMB10
2 Cross references
171 Possible Orthologues:

Proteasome 20s Subunit Beta 2

Ensembl ID : ENSUAMG00000001241
Gene Symbol: PSMB2
2 Cross references
220 Possible Orthologues:

Proteasome 20s Subunit Beta 4

Ensembl ID : ENSUAMG00000019433
Gene Symbol: PSMB4
2 Cross references
213 Possible Orthologues:

Proteasome 20s Subunit Beta 5

Ensembl ID : ENSUAMG00000008551
Gene Symbol: PSMB5
2 Cross references
218 Possible Orthologues:

Proteasome 20s Subunit Beta 6

Ensembl ID : ENSUAMG00000005403
Gene Symbol: PSMB6
2 Cross references
217 Possible Orthologues:

Proteasome 20s Subunit Beta 7

Ensembl ID : ENSUAMG00000025565
Gene Symbol: PSMB7
2 Cross references
216 Possible Orthologues:

Proteasome 20s Subunit Beta 8

Ensembl ID : ENSUAMG00000013929
Gene Symbol: PSMB8
2 Cross references
220 Possible Orthologues:

Proteasome 20s Subunit Beta 9

Ensembl ID : ENSUAMG00000013935
Gene Symbol: PSMB9
2 Cross references
212 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 2

Ensembl ID : ENSUAMG00000001899
Gene Symbol: PSMD2
2 Cross references
222 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 4

Ensembl ID : ENSUAMG00000027302
Gene Symbol: PSMD4
2 Cross references
270 Possible Orthologues:

Proteasome 26s Subunit, Atpase 2

Ensembl ID : ENSUAMG00000018974
Gene Symbol: PSMC2
2 Cross references
227 Possible Orthologues:

Proteasome 26s Subunit, Atpase 3

Ensembl ID : ENSUAMG00000005318
Gene Symbol: PSMC3
2 Cross references
226 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).